Fat-metabolism hypothesis
Laboratory and animal work linked the fragment with lipolysis and reduced fat accumulation.
Explore the research →BODY-COMPOSITION & GH-FRAGMENT RESEARCH
AOD-9604
A modified growth-hormone fragment explored for fat metabolism and weight management, although a meaningful weight-loss benefit has not been established.
Fat metabolismBody compositionGH-fragment biology
Studied in hundreds of people; obesity efficacy was not establishedAOD-9604 progressed through oral and intravenous human studies. The largest obesity programme did not produce significant weight loss versus placebo, making the difference between biological plausibility and demonstrated benefit especially important.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why does AOD-9604 still attract interest?
AOD-9604 was designed around an appealing idea: focus on the part of growth hormone associated with fat metabolism without recreating all of the hormone's other effects. That is why it became so closely associated with fat loss and body composition, with separate interest later developing around joints and cartilage.
Body-composition goals
Community use focuses on fat loss while trying to preserve training and lean tissue.
Explore the research →Selective GH-fragment biology
AOD-9604 was designed from amino acids 176–191 of human growth hormone with an added N-terminal tyrosine.
Explore the research →A valuable trial case study
AOD-9604 shows why an appealing mechanism must survive dose-ranging and placebo-controlled testing.
Explore the research →THE SCIENCE BIT
Testing a small part of growth hormone.
AOD-9604 was designed around a short region near the end of growth hormone. The aim was to explore fat-metabolism effects without reproducing the full hormone's growth-related action.
Laboratory and animal findings created a rationale for human trials. The larger obesity programme did not establish meaningful weight-loss efficacy, so the mechanism remains a research story rather than proof that it burns fat in people.
See the studies & trials →- GH fragment
- A selective design idea
- Lipid metabolism
- Experimental research focus
- Human trials
- The efficacy test matters
How this connects to the research
Preclinical rationale; obesity efficacy was not established in the larger human study.
FROM MOLECULE TO TISSUE
Where AOD-9604 connects with the body
These are the tissues and biological systems behind the interest in AOD-9604.
- Adipose tissue
- Fat-metabolism experiments.
- Metabolic systems
- Weight-related research.
- Connective tissue
- Separate exploratory interest.
The research behind the interest
Fat-metabolism hypothesis
Laboratory and animal work linked the fragment with lipolysis and reduced fat accumulation.
This provides a plausible mechanism, but a laboratory fat-metabolism signal is not proof of meaningful human fat loss.
Strong preclinical rationaleExplore the studies →Body-composition goals
Community use focuses on fat loss while trying to preserve training and lean tissue.
The largest controlled obesity study did not find significant weight loss compared with placebo despite diet and exercise support.
Human efficacy not establishedExplore the studies →Selective GH-fragment biology
AOD-9604 was designed from amino acids 176–191 of human growth hormone with an added N-terminal tyrosine.
Human safety summaries did not show the IGF-1 pattern expected from full growth hormone, but that distinction does not create proven efficacy.
Human exposure + mechanistic evidenceExplore the studies →A valuable trial case study
AOD-9604 shows why an appealing mechanism must survive dose-ranging and placebo-controlled testing.
Most identified obesity studies were negative, and development for obesity was terminated after the phase IIb programme.
Substantial but negative human programmeExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableTwelve-week oral AOD-9604 dose-ranging obesity study ↗
300 adults with obesity
Oral1, 5, 10, 20 or 30 mg once daily12 weeks
The largest reported numerical weight change occurred at 1 mg rather than rising with dose.
Limited abstract-level reporting and the non-linear pattern made the clinical meaning uncertain.
OPTIONS phase IIb obesity programme ↗
536 enrolled adults with obesity; approximately 502 analysed
Oral0.25, 0.5 or 1 mg once daily24 weeks with supervised diet and exercise
AOD-9604 did not produce significant weight loss compared with placebo.
The sponsor terminated development for obesity after the failed study.
Safety and tolerability of AOD-9604 in humans ↗
Participants across six randomized placebo-controlled studies
The publication summarized oral and intravenous human exposure and did not identify a full growth-hormone/IGF-1 pattern.
It does not validate modern compounded subcutaneous products or establish a beneficial dose.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceStrong
4/5 evidence depth
Several controlled studies exposed hundreds of people to oral or intravenous AOD-9604.
✓
Clinical efficacyEarly
1/5 evidence depth
The pivotal obesity programme failed to demonstrate significant weight loss versus placebo.
◇
Safety evidenceDeveloping
3/5 evidence depth
Short-to-medium-term trial safety data exist, but injectable community use, immunogenicity and long-term product-specific safety remain uncertain.
⌁
Preclinical evidenceStrong
4/5 evidence depth
Animal and laboratory studies support fat-metabolism and tissue hypotheses.
HOW TO READ THESE SCORESStrong preclinical evidence · strong human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
EVIDENCE LANDSCAPEAOD-9604Mechanism → measured response → clinical outcome
Multiple studies and a 24-week phase IIb programme
Largest controlled study did not beat placebo
No validated subcutaneous efficacy or dose conversion
Keep route, study setting and outcome together
A measured biological response can be valuable evidence without establishing a self-administered protocol or a durable treatment benefit.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with AOD-9604
AOD-9604 is explored mainly for fat loss, stubborn body-fat areas and a perceived 'non-growth' alternative to full growth hormone. The large human programme is highly relevant because it tested the central claim and did not confirm a meaningful obesity benefit.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Stubborn fat and a leaner appearance
People are drawn to the idea of influencing fat metabolism without using full growth hormone. The hoped-for change is usually a smaller waist or leaner look, even though human obesity research did not confirm a convincing weight-loss effect.
- What makes a report informative
- Weight and waist trends with the full diet and activity history.
- What can muddy the picture
- A proposed fat-related mechanism cannot overturn unsuccessful clinical weight-loss findings.
An addition when progress slows
Plateaus can prompt interest in adding another compound to a weight-loss or training plan. An apparent restart in progress is difficult to interpret when several changes happen together.
- What makes a report informative
- What changed in food intake, activity and other treatments.
- What can muddy the picture
- An add-on account cannot isolate an AOD-9604 effect.
Body composition with less GH-related concern
Interest sometimes reflects wanting fat-related effects without broader growth-hormone activity. That distinction explains the appeal but does not establish that the desired outcome occurs.
- What makes a report informative
- Actual body-composition outcomes rather than the mechanism alone.
- What can muddy the picture
- A narrower biological claim does not prove clinical efficacy or routine safety.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Stubborn-fat reduction
Users commonly pair daily use with a calorie deficit and increased activity, making attribution difficult.
Human findings & limits
The largest 24-week controlled trial found no significant weight loss versus placebo.
Laboratory & animal context
Mouse and adipose research supports a lipolysis hypothesis.
What this means: Biologically plausible, but contradicted by the strongest direct obesity trial.
Body recomposition without growth effects
Interest often rests on separating a GH fragment from full growth hormone.
Human findings & limits
Human safety summaries did not show a typical IGF-1 response, but body-composition efficacy was not established.
Laboratory & animal context
Fragment studies report metabolic rather than growth-promoting effects.
What this means: A meaningful molecular distinction that does not prove a practical benefit.
Easy daily microdosing
Flat subcutaneous amounts are widely repeated because they appear simple and compatible with training routines.
Human findings & limits
FDA found no human subcutaneous pharmacokinetic or efficacy study in its review.
Laboratory & animal context
Animal route data cannot supply human subcutaneous equivalence.
What this means: A recognizable community pattern with a major route-validation gap.
Plateau-breaking add-on
AOD-9604 is sometimes added when progress from diet, exercise or another medicine slows.
Human findings & limits
No controlled trial has tested it as a plateau-breaking add-on to modern obesity treatment.
Laboratory & animal context
Mechanistic overlap is not combination evidence.
What this means: Community rationale only; review the established plan before adding uncertainty.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
ONE ANECDOTAL COMMUNITY EXAMPLE
ANECDOTAL · UNVALIDATEDA flat daily community pattern—not a successful trial dose
The example below reflects recurring subcutaneous community discussion. Human obesity trials used oral or intravenous AOD-9604 and did not validate this route or a fat-loss result.
1Week 1
250 mcg · once dailyAnecdotal starting amount
2Weeks 2–4
250–300 mcg / dayOptional small community-described step
3Weeks 5–8
Continue only if reviewedNo evidence-based escalation
4After 8–12 weeks
Stop & reassessNo validated repeat-cycle interval
What people commonly discuss250–300 mcg subcutaneously once daily for roughly 8–12 weeks, usually alongside diet and training.
What remains unvalidatedNo human study validates subcutaneous bioavailability, this flat amount, a titration, meaningful fat loss or the proposed cycle and break.
ROUTE & DELIVERYThe pivotal human study used oral dosing
OPTIONS tested 0.25–1 mg oral doses for 24 weeks and did not show significant weight loss. Oral milligrams cannot validate injected micrograms.
PROFESSIONAL SOURCE CONTEXT
FDA AOD-9604 evidence review ↗The source shows what has actually been studied. It does not validate the community example above or turn it into guidance.
AOD-9604 has human oral and intravenous dose-ranging data, but no validated subcutaneous fat-loss dose or successful obesity regimen.
PUBLISHED HUMAN RESEARCH
View source ↗OPTIONS phase IIb obesity study ↗
Adults with obesity receiving diet and exercise support
WHAT THIS TRIAL EXAMPLE SHOWS
This was a published human study. It involved Adults with obesity receiving diet and exercise support. Route: Taken by mouth. The study lasted 24 weeks. The figures below describe the research design, not a personal schedule.
| First amount studied | 0.25 mg |
|---|---|
| Later or target amount | 1 mg |
| How often? | Once daily |
| How was it given? | Taken by mouth |
| How long? | 24 weeks |
See the exact study wording +
Start / initial: 0.25 mg
End / target: 1 mg
Frequency: Once daily
Route: Oral
Study duration: 24 weeks
The trial did not show significant weight loss versus placebo; these amounts are evidence of exposure, not a recommendation.
PUBLISHED HUMAN RESEARCH
View source ↗Early intravenous obesity study ↗
23 men with obesity
WHAT THIS TRIAL EXAMPLE SHOWS
This was a published human study. It involved 23 men with obesity. Route: Given into a vein (IV). The study lasted 4 weeks. The figures below describe the research design, not a personal schedule.
| First amount studied | 25 micrograms per kilogram of body weight |
|---|---|
| Later or target amount | 100 micrograms per kilogram of body weight |
| How often? | once a week |
| How was it given? | Given into a vein (IV) |
| How long? | 4 weeks |
See the exact study wording +
Start / initial: 25 mcg/kg
End / target: 100 mcg/kg
Frequency: Once weekly
Route: Intravenous
Study duration: 4 weeks
No significant weight-loss effect was established in this very small study.
COMMUNITY DISCUSSION
Anecdotal / unvalidated · no human subcutaneous efficacy studyWhat people commonly discuss
STARTING APPROACHES
Community protocol summaries commonly describe 250–300 mcg subcutaneously once daily, often without titration.
DURATION / CYCLES
Short 8–12-week cycles are frequently discussed alongside diet and resistance training.
MAINTENANCE DISCUSSION
A 4-week break is sometimes described, but no evidence-based washout, maintenance or repeat-cycle interval exists.
Community patterns are anecdotal and unvalidated unless a linked human study independently supports the same approach.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Daily editorial example
Community example · not clinically validatedHuman weight-loss research primarily tested oral AOD-9604 and did not establish efficacy. It does not validate this subcutaneous community pattern.
Form and route: Injection under the skin, as described in the example
| Calendar stage | Amount each time |
|---|---|
| Weeks 1–4 | 300 mcg |
| Weeks 5–12 | 500 mcg |
Frequency: Every day · 1 entry per scheduled day.
This is a finite editorial example. Its ending does not establish a safe course, break or repeat cycle. No repeat is added automatically.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Often combined with
OFTEN COMBINED WITH
Community rationale · component roles · evidence boundaryWhy people explore pairings with AOD-9604
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
Potential first, evidence in context. Pairings are usually explored because their research stories appear complementary. That makes them interesting to study, but does not yet prove extra benefit or safety.
CURRENT COMPOUNDAOD-9604
→
OFTEN EXPLORED WITHAOD-9604 + structured lifestyle programme
AOD-9604 + Nutrition and resistance training
→
OFTEN EXPLORED WITHAOD-9604 + GLP-1 clinical care
AOD-9604 + Prescribed incretin therapy
→
OFTEN EXPLORED WITHAOD-9604 + GH-axis peptides
AOD-9604 + CJC-1295 / Ipamorelin
Combination-specific human research is the strongest evidence for what a pairing adds. Evidence for either ingredient alone should not be silently transferred to the combination.
AAOD-9604 IS USUALLY DISCUSSED AROUNDA selective fat-metabolism hypothesis with failed obesity efficacy
＋AOD-9604's largest controlled programme did not produce significant weight loss despite supervised diet and exercise.
PTHE PAIRED APPROACH MAY ADDEstablished body-composition foundations or modern clinical treatment
Training, nutrition and indicated obesity medicines have their own evidence; no study proves that AOD-9604 adds to them.
＋
OFTEN EXPLORED WITH
Explore →＋AOD-9604 + structured lifestyle programme
AOD-9604 + Nutrition and resistance trainingWHY IT IS EXPLOREDPeople hope to add a selective fat-metabolism signal to an established body-composition foundation.
Diet and exercise were included in the failed phase IIb programme; added peptide benefit was not demonstrated.OFTEN EXPLORED WITH
Explore →＋AOD-9604 + GLP-1 clinical care
AOD-9604 + Prescribed incretin therapyWHY IT IS EXPLOREDCommunity discussion pairs a speculative lipolysis mechanism with established appetite treatment.
No controlled study establishes extra benefit, dosing or safety for the combination.OFTEN EXPLORED WITH
Explore →AOD-9604 + GH-axis peptides
AOD-9604 + CJC-1295 / IpamorelinWHY IT IS EXPLOREDThe pairing is framed as fat metabolism plus broader growth-hormone signalling.
No human combination trial supports synergy; overlapping metabolic and endocrine uncertainty increases monitoring needs.01Start with the proven layer
Nutrition, activity, sleep and indicated clinical care should remain visible rather than being credited to the peptide.
02Do not rescue a negative trial by stacking
A second compound cannot turn an unconfirmed AOD-9604 effect into evidence.
03Track body composition honestly
Weight, waist, strength and dietary adherence are more informative together than scale changes alone.
Safety context
SAFETY & UNCERTAINTY
Human exposure exists, but the popular injected route was not the tested obesity route
01ENCOURAGING CONTEXTHundreds of people received AOD-9604 in trials
Oral and intravenous studies provide more direct human exposure information than a purely preclinical peptide profile.
02THE IMPORTANT BOUNDARYThe pivotal efficacy result was negative
Most identified obesity studies failed to show benefit, and development for obesity stopped after the phase IIb programme.
03WHAT REMAINS UNKNOWNPopular subcutaneous use and compounded-product risk
Human subcutaneous pharmacokinetics, immunogenicity, impurity exposure, aggregation and long-term repeat-cycle safety are not established.
What the current evidence saysFDA's review highlighted uncertainty around subcutaneous exposure, immunogenicity, peptide aggregation, impurities and compounded-product quality. The failed efficacy programme also changes the risk–benefit balance: uncertain benefit makes avoidable product and injection risk harder to justify.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Different delivery routes have different absorption and exposure; the popular injected pattern was not the pivotal trial route.
Unapproved injectable products add contamination, concentration and degradation risks independent of the peptide theory.
When expected benefit is uncertain, injection and product risks carry proportionally more weight.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
5 sourcesSources used on this profile
Regulatory evidence reviewTwelve-week oral AOD-9604 dose-ranging obesity studyFDA evidence review ↗Peer-reviewed safety reviewSafety and tolerability of AOD-9604 in humansJournal of Endocrinology and Metabolism ↗Regulatory safety statusSafety and uncertaintyFDA compounding safety-risk list ↗Professional sourceUnited KingdomMHRA products database ↗Professional sourceUnited StatesFDA Drugs@FDA database ↗
CURRENT STATUS
How to interpret its position today
No UK-authorised medicine is represented on this profile
AOD-9604 is presented as a research compound. The MHRA products database should be checked for any future change in authorised status.
MHRA products database ↗No FDA-approved therapeutic product identified
Regulatory evaluation of a substance for compounding is separate from approval of a drug for safety and efficacy.
FDA Drugs@FDA database ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.